A large MedTech company, one of the market leaders in the IVF space, needed to consolidate the evidence base and clearly articulate the value proposition for one of its products.
Although some clinical and economic evidence existed, the number of available publications was limited, and the evidence had not been systematically synthesized. Internally, information was fragmented and primarily captured in basic Excel files and simple lists of publications.
In parallel, the company sought to use a comprehensive and methodologically robust document to support procurement negotiations across Europe and other global markets. Several tendering bodies requested a structured and transparent overview of the available evidence; however, the client lacked a credible, externally shareable document to support competitive procurement processes.
Within four months, MTRC developed a comprehensive value dossier for the product.
The dossier was built on a series of systematic literature reviews designed to address key research questions, including:
- Epidemiology and burden of disease for the target conditions, with particular attention to the legal and regulatory aspects of the IVF market
- Current IVF techniques and their limitations
- Description and positioning of the target technology
- Systematic literature review of clinical effectiveness, safety, organizational impact, and staff satisfaction associated with the technology
- Systematic literature review of cost implications and resource utilization following implementation of the technology
The value dossier synthesized evidence from more than 35 studies. The final document comprised approximately 42 pages, plus appendices. All methodological steps were fully documented to ensure transparency and credibility, including:
- Search strategies (MEDLINE, MEDLINE In-Process, EMBASE, Cochrane Library)
- Inclusion and exclusion criteria
- PRISMA flow diagrams
- Lists of excluded studies with justifications
This level of rigor facilitated review by reimbursement authorities and health technology assessment (HTA) bodies.
The value dossier delivered immediate strategic value:
- It clarified the existing evidence base and articulated comprehensive value propositions for patients, payers, healthcare providers, and clinical staff
- It identified key evidence gaps that could be addressed to strengthen the product’s future positioning
Following a thorough internal review, including verification of all references, the dossier was formally approved for external use. It was subsequently deployed in procurement discussions and was immediately used to support a major tender submission in a Western European country.
Get in Touch
Contact us to discuss your needs and learn about our services